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(presented  by  the  Commission) Explanatory  Memorandum 
1.  The  report  annexed  deals with  the main  considerations  that  need  to  be  taken 
Into  account  In  connection  with  the  authorization  and  use  of  Bovine 
Somatotrophln  (BST).  When  administered  to  the  lactating cow  BST  Is  capable 
of  bringing  about  a  significant  Increase  In  milk yield. 
2.  The  existing  authorization  arrangements  In  relation  to  BST  provide  for  a 
national  decision-making  procedure  after  the  Committee  on  Veterinary 
Medicinal  Products  (CVMP)  establ lshed  under  Directive  81/851/EEC  has 
del lvered  an  opinion.  The  Committee  Is  expected  to  Issue  an  opinion on  two 
appl !cations  In  relation  to  BST  within  the  next  six months. 
3.  The  conclusion of  the  report  Is  that  It  would  be  Inappropriate  to  decide on 
the  use  of  BST  unt I I  a I I  the  necessary  studIes  and  assessments  have  been 
completed.  Furthermore  a  decision on  BST  should  awalt  the  putting  In  place 
of  revised  dispositions  In  relation  to  veterinary  medicinal  products  and 
feed  additives  Intended  for  promotion  of  yield.  Present  Indications  are 
that,  apart  from  BST,  other  comparable  products  applied  to  livestock  may 
have  a  significant  effect  on  productl.vlty,  with  potentially  far  reaching 
lmpl !cations  for  production and  soclo/economlc structures  In  agriculture. 
4.  It  Is,  accordingly,  proposed  to  the  Council  to  adopt  the  annexed  proposal 
with  a  view  to  establishing  an  evaluation .period,  until  31  December  1990 
as  regards  the  admlnlstrat lon  of  BST.  T'here  are  no  lmpllcat Ions  for  the 
Community  budget. Draft  Proposal 
for  a 
counc II  Dec Is ton 
of 
Concerning  the  administration of Bovine  Somatotrophln  (B.S.T.} 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES 
Having  regard  to  the  Treaty  establishing  the  European  Economic  Community,  and 
In  particular Arttcle 43  thereof, 
Having  regard  to the  proposal  of  the Commission, 
Having  regard  to the opinion of  the  European  Parliament, 
Having  regard  to the opinion of  the  Economic  and  Social  Committee, 
Whereas  products  arising  from  milk  production  have  a  very  Important  place  In 
the  Community;  Whereas  they  are  an  essential  source  of  Income  for  a  part  of 
the agricultural  population; 
Whereas  knowledge  acQuired gives  the possibility for  the  placing on  the market 
of  substances  which  may  have  a  significant  Impact  on  productivity  In  milk 
production; 
Whereas  despite  the  work  accomplished,  In  particular  the  evaluation of  Bovine 
Somatotrophln  by  the  Committee  on  veterinary  Medicinal  Products  In  accordance 
with  Council  Directive 81/851/EEC  of  28th  September  1981  on  the  approximation 
of  the  I  aws  of  the 
products< 1 >  and  Counc I 1 
Member  States  relating  to  veterinary  medicinal 
Directive  87/22/EEC  of  22nd  December  1986  on  the 
approximation  of  national  measures  relating  to  the  placing  on  the  market  of 
high-technology  medical  products,  particularly  those  derived  from 
blotechnology<2>,  the  various effects of  new 
---------------------------------------------------
( 1 )  O.J.  NO  L 317  of  06 . 11 . 1981 •  p,  1 
(2)  O.J.  NO  L  15  of  12.01.1987,  P.  38 
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substances  such  as  Bovine  Somatotrophln  are  not  yet  sufficiently  clear;  In 
this  respect,  a  necessary  period  should  be  forseen  for  In-depth  studies  to  be 
made; 
Whereas  In  the  absence  of  a  Community  decision,  the  Member  States  may  adopt 
divergent  measures;  whereas  these  divergencies  may  lead  to  a  distortion  of 
competition  between  milk  producers  and  to  new  barriers  to  Intra-Community 
trade; 
Whereas  In  the  view  of  the  preceedlng  considerations,  It  Is  a  matter  of 
overriding  publ lc  Interest  to  provide  for  a  temporary  prohibition  of 
administration  to  dairy  cows  of  the  substances  In  question,  untl I  al 1 
necessary  Information  Is obtained; 
Whereas  It  wll I  be  necessary  to  re-examine  the overall  situation. 
HAS  ADOPTED  THIS  DECISION: 
Article  1 
Notwithstanding  the  scientific  and  technical  examination  of  applications  In 
accordance  with  Community  legislation,  until  31  December  1990  the 
administration  by  any  means  whatsoever  within  t~ Community  to  dairy  cows  of 
Bovine  Somatotrophln,  shall  not  be  authorized  In  the  Member  States. 
Article 2 
In  derogat Jon  from  Art lcle  1,  the  Member  States  may  author lse  the 
administration  to  dairy  cows  of  Bovine  Somatotrophln  for  carrying  out 
scientific and  technical  trials. - 3  -
Article 3 
On  a  proposa I  from  the  Comm Iss Jon  the  Counc II  may.  act lng  by  a  qua II fled 
maJority,  adopt  measures  necessary  for  the  Implementation  of  this Decision. 
Article  o4 
The  Commission  shall,  before  1  October  1990,  submit  a  report  to  the  Council 
and  to  the  European  Parliament  on  the  development  of  the  situation, 
aceompan led  by  any  necessary  proposa Is.  The  Counc I I  sha II  dec I  de  before  31 
December  1990. 
Article 5 
This  Decision  Ia  addressed  to  the Member  States. 
Done  at Brussels 
Sy  the  Counc II REPORT 
from  the  Commission  to  the  Councl I 
and  to  Par I I ament 
concerning 
Bovine  Somatotrophln  (B.S.T.) Report  from  the  commission  to  the  Council 
and  to  Parliament  concerning 
Bovine  Somatotrophln  CB.S.T.) 
GENERAL  BACKGROUND 
1.  Somatotrophtn  Is  a  growth  hormone,  secreted  by  the 
pituitary  gland.  In  general  the  activity  of  this  hormone 
Is  species  specific,  so  that  for  example,  Bovine 
Somatotrophln  (BST)  from  the  cow  should  have  no  Influence 
on  human  growth.  It  has  been  known  since  the  1930s  that 
the  administration  of  BST  to  dairy  cattle  could  Increase 
milk  yields.  However,  since  BST  could  only  be  extracted  as 
a  natural  hormone  post  mortem,  the  quantities  available 
were  too  I lmtted  and  too  expensive  to  permit  commercial 
use. 
2.  Fol towing  the  development  of  recombinant  DNA  biotechnology 
In  the  1970s,  It  became  possible  to  produce  large 
quantities of  somatotrophtns  at  relatively  low  cost.  Apart 
from  use  of  recombinant  BST  (rBST)  for  milk  production, 
for  which  authorisation  Is  now  being  sought  by  the 
companIes  concerned,  research  Is  beIng  conducted  Into  use 
of  bovine,  porcine  and  ovlne  somatotrophlns  for  fattening 
purposes. 
3.  A  further  factor  delaying  the  commercial  exploitation  of 
BST  was  the  need  to  provide  an  appropriate  sustained 
release  formulation,  which  would  eliminate  the  need  for 
dally  InJections.  The  stage  has  now  been  reached  where 
administration  at  two  to  four  weekly  Intervals  seems  to 
bring  about  the  desired  Increase  In  milk  yields.  Studies 
have  Indicated  Increases  of  milk  yield  of  upwards  of  25%  on 
administration  of  rBST  under  controlled  conditions.  It  Is - 3  -
estimated  that,  given  the  knowledge  and  ability  required 
for  effective  use  of  the  product,  yield 
to  12%  are  more  likely  to  be  achieved 
conditions. 
Increases  closer 
In  normal  farm 
4.  The  possible  use  of  rBST  In  milk  production  has  been  the 
subJect  of  widespread  public  Interest.  In  the  Council  of 
Agriculture  Ministers  several  Member  States  have  expressed 
reservations  about  Its  use,  mainly  In  relation  to 
potentially  adverse  soclo/structural  consequences  and  the 
lmpllcat Ions  as  regards  supply  and  demand  for  milk  and  milk 
products.  The  matter  has  been  examined  extensively  by 
various  Committees  In  the  European  Parliament  which,  on 
5  July  1988,  adopted  a  resolutlon1  on  the  effects  and 
risks  of  using  growth  hormones  and  the  BST  hormone  In  the 
dairy  and  meat  Industries.  The  Parliament  called  on  the 
Commission  to  examine  the  consequences  of  the  use  of  rBST, 
to  consider,  Inter  alia,  the  necessity  for  additional 
criteria,  e.g.  social  and  economic  factors,  In  the 
examination  of  appl lcatlons  for  authorisations  and  to 
create  a  legal  framework  covering  genetically  engineered 
growth  accelerators  or  yield  enhancers.  Under  existing 
legislation  authorisations  are  considered  on  the  basis  of 
three  criteria  viz,  safety,  quality  and  efficacy.  The  BST 
question  was  discussed  at  length  at  a  seminar  held  In 
September  1988  under  the  auspices  of  the  Commission.  A 
wide  range  of  organisations  (listed  In  Annex  1}  have  been 
consulted  and  have  had  an  opportunity  to  give  their  views. 
5.  It  Is  clear  from  the  reaction  In  the  Council  of  Ministers 
that,  while  most  Member  States  are  very  hesitant  about 
the  authorisation  of  rBST,  there  may  not  be  unanimity  on 
the  Issue.  Divergent  positions  of  Member  States  on 
authorisation  carries  a  serious  danger  of  distortion  of 
competition  and  trade  disputes. 
O.J.  c  235  (Vol.  31}  of  12.9.1988,  pp.  41-44. - 4  -
EXISTING  LEGISLATION 
6.  The  definition  of  a  medicinal  product  In  Article  1  of 
Directive  65/65/EEC  covers  not  only  products  Intended  to 
prevent  or  treat  disease  but  also  products  which  may  be 
administered  to  humans  or  animals  with  a  view  to  modifying 
physiological  functions,  such  as  an  Increase  In  milk  yield 
In  cattle.  BST  Is  therefore  regarded  as  a  vet~rlnary 
medicinal  product. 
7.  Directive  81/851/EEC 
the  Member  States 
medicinal  products. 
matter  for  decision 
Is  designed  to  harmonize  the  laws  of 
on  the  authorization  of  veterinary 
The  approach  to  authorisation  a 
by  the  Member  State  concerned  Is 
based  on  three  exclusive  criteria  namely  quality,  safety 
and  effIcacy  of  the  products  concerned.  The  procedure  In 
the  case  of  biotechnology  products  Is  somewhat  different  In 
that  under  Directive  87/22/EEC,  Member  States  may  not 
decide  on  any  application  for  authorization  for  a 
veterinary  medicinal  product  derived  from  biotechnology 
untl I  the  Committee  for  Veterinary  Medicinal  Products 
(CVMP)  has  given  an  opinion.  Final  evaluation  of  the  test 
results  and  the  decision  on  authorization  remains  the 
responslbl I lty of  the  Member  States. 
8.  As  regards  other  comparable  legislation  In  agriculture 
somatotrophln  Is  not  subJect  to  Council  Directives 
1981/602/EEC  of  31  July  19812,  85/358/EEC  of  16  July 
19853  and  88/146/EEC  of  7  March  19884  In  relation  to 
prohibition  on  the  use  of  certain  hormones  for  fattening 
purposes.  It  Is  not  affected  either  by  the  provisions  of 
Counc I I  DIrectIve  70/524/EEC  of  23  November  1970  on 
additives  In  feedlngstuffs.5  Under  this  Directive  the 
only  substances  that  may  be  used  as  additives  In  animal 
2  O.J.  L  222  of  7.8.1981,  p.  32. 
3  O.J.  L  191  of  23.7.1985,  p.  46. 
4  O.J.  L  70  of  16.3.1988,  p.  16. 
5  0. J.  L  270  of  14. 1 2. 1979,  p.  1 . 
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feedlngstuffs  are  those  approved  by  a  Community  procedure 
and  listed  In  the  Annexes  to  the  Directive.  Since  no  oral 
preparation  Is  currently  available  In  the  case  of  rBST-
formulations  are  administered  by  Injection- the  question 
of  authorising  rBST  as  an  additive  In  feedlngstuffs  has  not 
arisen.  It  may  be  noted,  however,  that  several  antibiotics 
and  other  chemical  additives,  whose  effect  Is  to  Increase 
productivitY  of  livestock,  are  either  currently  authorised 
or  the  subject  of  applications  for  authorisation. 
9.  Two  applications  for  a  marketing  authorization  for  BST  were 
referred  for  an  opinion  to  the  CVMP  In  1987.  One 
application  would  cover  all  Member  States  except 
Luxembourg  and  the  Netherlands.  A  second  application 
concerns  France  and  the  United  Kingdom. 
Under  existing  procedures  It  Is  a  matter  for  the  applicant 
to  submit  the  data  necessary  to  prove  that  the  three 
criteria  have  been  met;  applications  are  assessed  by  the 
national  authorities  and  by  the  Committee.  The 
authorities  of  the  Member  States  concerned  receive  a 
complete  set  of  the  data  submitted  by  each  company,  and 
have  the  opportunity  to  submit  questions  and  comment. 
The  commercial  Implications  of  receiving  authorisation 
requires  that  the  regulatory  authorities  protect  the 
confidentiality  of  the  data  submitted.  The  Commission  Is 
obliged  also  to  respect  the  confidentiality  of  discussions 
within  the  CVMP,  a  requirement  that  limits  the  degree  of 
detal I  that  can  be  furnished  In  this  report. 
10.  In  Its  examination  of  this  matter  the  CVMP  has  been 
assisted  by  an  ad-hoc  group  of  experts  on  biotechnology. 
It  Is  understood  that  the  assessment  process  within  the 
Committee  may  be  entering  Its  final  phase.  Expectations 
are  for  an  opinion  In  or  about  the  end  of  this  year.  At 
this  stage,  therefore,  It  Is  only  possible  to  provide  an 
Interim  review  of  the  authorisation  process. - 6  -
EXAMINATION  BY  COMMITTEE  ON  VETERINARY  MEDICINAL  PRODUCTS  (CVMP) 
11.  Following  Is  an  Indication  of  progress  on  the  main  elements 
taken  Into  account  In  the  Committee's  assessment. 
a)  Safety  In  the  animal 
The  studies  InitIally  submitted  by  the  applicants  were 
considered  to  be  of  Insufficient  duration.  Both  applicants 
have  been  requested  to  provide  substantial  additional  data 
covering  three  lactation  periods;  this  Involves  the 
monitoring  of  a  wide  range  of  physiological  parameters  In 
the  cow  and  her  progeny  to  enable  a  comprehensive 
assessment  to  be  made.  Among  the  factors  which  are  being 
specifically  considered  under  this  heading  are  the 
potentIa I  effects  of  BST  on  reproduct lve  performance,  on 
the  Incidence  of  mastitis,  on  bone  growth  and  development 
In  the  calf  and  on  the  extent  and  cl lnlcal  significance  of 
InJection  site  reJections. 
b)  Human  safety 
It  Is  assumed  at  present  that  any  residues  of  BST  In  ml lk 
should  not  pose  a  risk  to  consumer  health  since  the  overal 1 
level  of  BST  Is  not  significantlY  Increased  after 
administration.  Besides,  BST  Is  destroyed  during 
pasteurization,  the  hormone  Is  broken  down  completely  In 
the  stomach  and  Is  not  active  In  man.  The  applicants  have 
been  required  to  provide  scientific  data  to  Justify  these 
assumptions.  Since  BST  operates  either  directly  or  via 
stimulation  of  another  hormone  (IGFI)  the  effect  as 
regards  other  hormone  levels  has  to  be  considered  also. 
While  BST  Is  designed  to  Increase  milk  yields, 
consideration  must  be  given  also  to  residues  of  BST  In 
meat,  In  particular  to  any  persistence  of  residues  at  the 
InJection  site.  As  with  any  veterinary  medicinal  product, 
the  appl lcant  must  propose  a  routine  method  of  analysis  of 
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sufficient  sensitivity  to  detect  residues  at  low  levels. 
Moreover,  In  addition  to  studies  of  the  safety  of  residues, 
the  potential  risk  of  direct  human  contact  with  the 
products  must  be  addressed  to  ensure  the  safety  of  persons 
using  the  product  on  the  farm.  These  elements  form  part  of 
the  assessment  by  the  Committee. 
c)  QualitY  of  synthetic  B.S.T. 
Wh  I I e  BST 
commercial 
Is  a  naturally 
formulations  are 
occurring  substance,  the 
complex  products  requiring 
advanced  technology  In  manufacture.  The  applicants  have 
had  to  provide  appropriate  guarantees  of  their  ability  to 
produce  a  consIstent,  pure  and  homogenous  product  on  an 
Industrial  scale. 
d)  Efficacy  of  synthetic B.S.T. 
While  the  effect  of  BST  In  Increasing  milk  yields  Is  well 
documented,  further  Information  has 
Justify  the  proposed  dosage  levels 
between  InJections. 
12.  Resume  of  examination  by  CVMP 
been  requested  to 
and  the  Intervals 
The  various  elements  Involved  are  stl I I  under  assessment  by 
scientists  from  the  national  regulatory  authorities. 
The  examination  process  Is  now  entering  Its  final  phase; 
It  Is  expected  that  an  opinion  will  be  delivered  by  the 
committee  by  the  end  of  the  year. 
OTHER  IMPACTS 
13.  Apart  from  the  examination  by  the  Commltttee,  some  of  the 
elements  Involved  are  the  subject  of  other  studies  being 
carried  out  at  the  request  of  the  Commission  eg  on  quality 
and  composition  of  the  product,  and  likely  consumer  and 
producer  attitudes  to  the  use  of  BST.  Other  Important - 8  -
socio-economic  and  economic  factors 
agr 1  cuI tura I  product I on  and  structures 
the  subJect  of  In-depth  studies. 
Food  Product  Qual lty 
eg  effects  on 
are  not  at  present 
14.  As  regards  milk  quality,  apart  from  the  safety  of  residues, 
the  applicants  for  authorisation  must  IdentifY  any 
potential  difficult les  In  the  subsequent  Industrial 
processing  of  foodstuffs.  In  the  course  of  examination  by 
the  CVMP,  additional  Information  has  been  required  on  the 
effects  of  the  use  of  BST  on  protein,  fat  and  vitamin 
content  of  milk  and  on  the  effects  for  the  manufacture  of 
cheeses  and  other  dairy  products. 
15.  An  aspect  requiring  particular  attention  relates  to  the 
somatic  cell  count  (SCC)  which  Is  one  of  the  main  tests  of 
milk  bacteriological  quality  and  Is  used  as  an  Indication 
of  mastitis  In  animals.  Reports  from  the  United  States  and 
a  recent  German  study  (Heeschen  1988),  Indicate  that  SST-
application  leads  to  an  Increased  number  of  somatic  cells 
In  the  milk  and  to  Increased  pyruvate  levels  also. 
Increased  sec  levels  would  have  Implications  as  regards 
the  standards  1  aId  down  In  DIrectIve  85/397  as  regards 
Intra  Community  trade  In  milk  for  consumption  and  the  price 
pa 1  d  to  producers  for  m I I k  for  manufactur 1  ng.  An  I ncr ease 
In  somatic  cells  affects  the  composition  of  milk  eg  the 
lactose/salts  ratio,  a  factor  that  could  Influence  product 
quality  and  yield.  A  research  proJect  Is  currently 
underway  (funded  by  resources  from  the  milk  co-
responsibility  levy)  at  the  Bundesanstalt  fur 
Mllchforschung  at  Klel  to  examine  these 
Is  expected  by  the  end  of  1990. 
aspects;  a  report 
16.  The  standard  of  farm  management  Is  essential  If  the  likely 
adverse  effects  of  BST  on  composition  are  to  be  mitigated. 
The  availability of  good  quality  feeding  and  the  ability of 
the  cow  to  consume  It  In  Increased  amounts  Is  a 
prerequisite  to  effective  application  of  rBST.  Should 
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producers  fall  to  operate  an  adequate  feeding 
fatty  acid  composition  of  milk  fat,  and  In 
quality,  would  be  affected. 
system,  the 
turn  butter 
The  Impact  of  BST  on  ml lk  composition  needs  to  be  examined 
more  fully,  In  relation  to,  for  example,  milk 
concentration,  the  combination  effects  of  heat  treatments 
and  the  effects  on  rennetablllty,  the  effect  of  Increases 
In  the  level  of  whey  proteins  and  consequences  for  the 
consumpt ton  of  liQUid  milk.  These  are  quest Ions  that  need 
to  be  addressed  by  way  of  further  studies. 
ECONOMIC  AND  SOCIAL  CONSEQUENCES 
Impact  at  far•  level 
17.  The  consequences  have  to  be  considered  In  the  context  of 
the  milk  quota,  established  as  part  of  the  Community's 
milk  policy,  remaining  beyond  Its  review  date  In  1992. 
At  the  Individual  farm  level  the  main  consequence  of  the 
I nt roduct I on  of  rBST  In  m I I k  product I on  1 s  an  I ncr  ease  In 
the  milk  yield  per  cow.  The  actual  level  of  milk  yield 
Increase  would  be  less  (probably  about  12%)  than  the  25% 
recorded  In  rasearch,  s I nee  farm  management  1  n  norma I 
circumstances  Is  likely  to  be  less  rigorous  than  under  the 
highly-controlled  conditions  of  experimental  studies. 
While  Intake  of  feed  has  to  Increase  significantly,  perhaps 
by  as  much  as  10%,  to  achieve  optimum  results,  BST  can  lead 
to  an  Increase  In  the  efficiency  of  feed  conversion  to  milk: 
by  up  to  6%.  There  Is  a  view  that  on  many  farms  BST  may 
be  used  as  a  tactical  management  tool,  for  example  to 
Increase  milk  output  where  product ion  seems  likely  to  fall 
below  quota,  or  to  adJust  the  seasonality  of  production  or 
to  treat  Individual  cows,  rather  than  as  a  routine 
treatment. - 10  -
While,  In  the  Initial  period  at  least,  the  response  to  BST 
by  way  of  Increased  milk  yield  at  farm  level  may  be  below 
the  research  levels,  It  Is  reasonable  to  expect  a  growing 
Increase  In  yield  levels  as  further  research  and  management 
are  refined  to  achieve  optimum  results.  It  has  to  be 
assumed  that  BST  would  be  made  available  at  a  price  to 
permit  economic  use. 
18.  The  Community's  milk  quota  regime  Is  designed  to  ensure 
that  milk  production  does  not  Increase  beyond  a  fixed 
level.  Nevertheless,  the  present  tendency  for  large  scale 
dairy  farmers  to  produce  In  excess  of  their  Individual 
quotas  creates  an  ongoing  risk  of  higher  milk  deliveries. 
BST  would  add  to  this  risk.  Furthermore  Its  use  by  milk 
producers  to  avoid  production  being  under  quota  would 
remove  an  Important  "safety  valve"  from  the  existing 
system. 
19.  The  general  use  of  BST  would  likely  lead  to  reduced  dairy 
cow  numbers.  This  would  affect  the  beef  sector  through  an 
Increase,  In  the  short-term,  In  the  number  of  cows  taken 
out  of  milk  production  and  sent  for  slaughter.  In  the 
longer-term  fewer  dairy  cows  should  lead  to  lower  beef 
production.  In  the  normal  course  le  without  BST,  beef 
production  from  the  dairy  herd  would  tend  to  fall  due  to 
the  ongoing  Increase  In  milk  yield  as  a  result  of  Improved 
feeding  and  housing  techniques  and  better  selection  In  the 
dairy  herd.  The  use  of  BST  would  accelerate  this  trend; 
some  studies  suggest  that  the  decline  In  cow  numbers 
would  accelerate  by  some  10  percent. 
20.  Reduction  In  dairy  cow  numbers  raises  the  question  of  the 
utilisation  of  the  factors  of  production,  I.e.  labour  and 
capital,  that  would  be  freed  at  the  farm  level.  Many 
farmers  affected  by  the  milk  quota  are  already  starting  new 
enterprises,  especially  In  beef,  sheepmeat  and  cereals. 
This  tendency  could  grow  despite  there  being  few  Increased 
outlets  for  further  production;  beef  and  cereals  are 
subject  to  the  stablllser  mechanisms,  wh lie  sheepmeat  has 
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been  the  subject  of  proposals  designed  to  reduce  the 
guarantee,  In  vIew  of  the  sharp  rIse  In  FEOGA  expendIture 
In  the  sector.  The  development  of  opportunities  for 
diversification  and  alternative  rural  enterprises  could  be 
a  factor  also. 
Ml lk  PolleY  Aspects 
21.  In  considering  this  question  It  Ia  necessary  also  to  bear 
In  mind  the  agricultural  policy  pursued  In  recent  years  by 
the  Community,  notably  since  1984.  This  has  Involved  a 
programme  to  control  output  directly  and  to  encourage 
farmers  to  diversify  and  engage  In  less  Intensive  forms  of 
production.  The  policy  was  developed  against  a  background 
of  sharply  Increasing  production,  and  mounting  surpluses 
leading  to  unsustainable  pressures  on  the  Community  budget. 
22.  Despite  the  quota  system  and  a  satisfactory  market 
situation,  the  milk  regime  costs  about  5  000  MECU 
annually.  The  quota,  central  to  the  Community's  policy  of 
containing  production  and  expenditure,  Is  a  fragile 
mechanism  whose  beneficial  effects  are  at  constant  risk 
from  surplus  production.  Deliveries  In  the  1988/89  season 
were  some  1.8  ml II lon  tonnes  above  quota;  this  has  led  to 
requests  to  the  budgetary  author lty  for  Increased  credits 
for  the  milk  sector  this  year. 
Soclo-Structurat 
23.  As  regards  the  soclo-structural  aspects,  milk  production 
Is  central 
loss  than 
represent 
daIry  cows 
to  Incomes  of  smaller  producers  le  those  with 
10  cows  In  the  Community.  While  such  producers 
some  53%  of  holdings  (1.6  million),  only  12%  uf 
are  kept  on  their  holdings.  Producers  wl n, 
larger  resources  are  best  placed  to 
through 
take 
the 
advantage  of 
Increases  In  productivity  use  of  new 
technologies.  smaller 
capab!e 
are  sl'w 
of  adapting 
producers,  traditionally  less 
lo  change  and  technical  advan..:es 
If  at  alI,  from  such  opportunities. - 12  -
In  the  case  of  BST,  the  management  techniques  required  and 
the  need  to  provide  supplementary  high  quality  feed  for 
cows,  would  limit  any  possible  advantages  In  the  case  of 
small  herds.  Besides,  there  would  normally  be  no 
Incentive  to  a  herdowner  with  less  than  a  given  minimum 
number  (8)  of  cows  to  use  BST.  This  would  have 
Implications  as  regards  the  regional  distribution  of  BST 
usage  In  the  Community. 
24.  The  ability  of  BST  to  Increase  further  the  economies  of 
scale  and  profits  of  larger  producers  would  give  them  a 
greater  capacity  to  engage  In  other  forms  of  production 
and/or  to  purchase  smaller  holdings  with  milk  quotas.  It 
Is  likely  also  to  lead  to  growing  pressures  to  break  the 
I Ink,  In  existing  legislation,  between  the  quota  and  the 
holding  -quotas  may  not  be  purchased  Independently  of  the 
corresponding  holding  as  larger  producers  seek  to 
consol ldate  their  positions  and  make  optimum  use  of  the  new 
technology. 
25.  Consumer  VIew 
No  detailed  studies  have  been  made,  of  the  likely  consumer 
reaction  to  meat  and  dairy  products  In  the  event  of  BST 
being  authorised.  Consumers  organisations  have  warned 
that  this  could  be  very  negative.  At  the  meeting  of  the 
Veterinary  Advisory  Committee  on  15  March  and  at  the 
Advisory  Committee  for  milk  and  milk  products  on  31  March 
1989.  BEUC,  the  umbrella  consumer  group  organization, 
called  for  a  total  ban  on  BST.  The  consumer  view  Is  that 
research  carried  out  to  date  does  not  demonstrate  any 
advantage  for  the  consumer  eg  by  reducing  retal I  prices  for 
dairY  products  or  by  Improving  the  quality  of  milk  and 
meat  products  or  the  health  and  nutritional  standards  of 
milk.  On  the  contrary  BST  Is  claimed  to  engender 
mistrust  and  suspicion  of  the  quality  of  meat  and  of  dairy 
products.  Consumers  are  concerned  also  at  the  animal 
welfare  aspects  (see  par  29). 
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26.  Market  Aspects 
27. 
As  regards  the  market  for  dairy  products,  consumption  has 
been  IncreasIng  stead I I y  In  recent  years.  There  1  s  a 
growing  trend  away  from  traditional  products  such  as  butter 
- perceived  by  some  consumers  as  harmful  to  health  - to 
cheeses  and  diversified  products.  Dairy  products  face 
Increasing  competition  from  substitute  products. 
Producers,  the  dairy  Industry  and  Indeed  the  Community, 
through  some  400  MECU  committed  from  the  coresponslblllty 
funds,  have  Invested  heavily  In  recent  years  In  promoting 
an  Image  of  milk  and  dairy  products  as  natural,  healthy 
products. 
It  would  be  a  serious  setback 
Community's  ml lk  pol Icy  were 
to  producers 
present 
and  to 
trends 
the 
In 
consumption  to  be  reversed  as  a  result  of  adverse  consumer 
reaction.  This  points  to  the  need  for  the  most  careful 
evaluation  of  this  aspect.  Since  existing  techniQues  do 
not  permit  the  ready  Identification  of  rBST  In  dairy 
products,  the  concerns  of  consumers  cannot  at  present  be 
met  through  labelling.  An  Important  research  project, 
financed  by  the  milk  co-responsibility  funds,  Is  being 
carried  out  at  the  University  of  Munich  with  the  object  of 
finding  a  method  to  Identify  rBST  In  milk:  this  Is 
expected  to  be  completed  In  the  second  half  of  1990. 
28.  It  Is  Intended  that  other  studies  currently  under  way  at 
the  Institute  fUr  Wlrtshaftsforshung  In  Munich  and  at  the 
University  of  Glessen  due  to  be  completed  In  November  1990 
will  provide  more  Information  on  likely  consumer  reaction. 
The  studies  wl I I  cover  farmer  reaction  also  to  use  of  BST. 
29.  Animal  Welfare 
Concern  at  the  animal  welfare  Implications  of  the  use  of 
BST  relates  to  short-term  and  long-term  effects,  and 
administration.  As  regards  the  short-term,  the  concern  Is 
that  cattle  treated  with  BST  could  suffer  from  a  greater - 14  -
Incidence  of  metabolic  diseases.  In  relation  to  the  longer 
term  the  concern  Is  that  the  administration  of  BST  over 
several  lactations  could  result  In  changes  In  the 
calcium/phosphorus  balance,  leading  to  musculo-skeletal 
deformities,  and  that  there  could  be  unforeseen  problems 
for  the  calves  of  treated  cows.  The  CVMP  Is  examining  these 
aspects. 
The  need  to  administer  BST  by  Injection  and  to  restrain 
animals  for  the  purpose  of  administration  are  seen  also  as 
undesirable  on  animal  welfare  grounds. 
30.  Other  Somatotrophlns 
While  the  Immediate  subject  of  this  report  relates  to  rBST 
for  ml lk  production,  somatotrophln  has  a  potential  to  be  an 
effect lve  commercial  growth  and  carcase  enhancer  In  other 
livestock.  Significant  Improvements  In  dally  gains  and 
feed  conversion  efficiency  have  been  recorded  In  the  course 
of  experimental  work  on  cattle,  sheep  and  especially  In 
pigs.  While  results  are  more  variable  than  In  the  case  of 
milk  and  the  techniques  Involved  have  not  reached  the  stage 
of  commercialisation- the  need  for  frequent  Injections  Is 
a  major  drawback  further  research  and  development  In 
these  fields  may  open  the  way  for  a  substantial  Increase  In 
productivity  and  production  of  I lvestock  products. 
31.  VIews  of  Pharmaceut lea I  Industry 
The  pharmaceutical  Industry  would  be  concerned  about 
possible  adverse  Impact  of  changes  In  present  authorisation 
procedures  not  founded  on  a  sound  scientific  basis.  The 
Industry  would  be  opposed  to  criteria  relating  to  social 
and  economic  factors.  The  content Jon  Is  that  departures 
from  criteria  established  by  legislation  create 
uncertainty,  and  reduce  the  likelihood  of  research, 
development,  Innovation  and  Investment. - 15  -
The  Industry  supports  the  authorization  of  BST  which,  It 
claims,  will  bring  economic  benefits  for  Industrial 
supp I I er,  farmer  and  consumer. 
Feed  Additives 
32.  Apart  from  BST,  concern  has  been  expressed  In  the  Council 
of  Ministers  In  relation  to  the  authorisation  of  growth 
promoters  In  animal  feedlngstuffs  (see  par  8).  This 
concern  relates  to  Owconsumer  protection,  market  Jmbalanc 
and  budgetary  costs.  The  Commission  has  undertaken  to 
present  the  results  of  studies  In  this  area  with  a  view  to 
discussion  In  Council.  It  Is  accordingly  Intended  to 
launch  shortly  a  wide-ranging  study  of  the  Impact  of 
growth  factors  In  the  product Jon  of  livestock  products. 
This  wl I I  cover  the  economic  aspects  In  relation  to 
agricultural  productivity,  research  and  consumption; 
together  with  the  socio-economic  elements.  The  study  Is 
expected  to  be  completed  by  October  1990.  Nine  growth 
promoters  have  been  authorised  as  feed  additives  under 
existing  legislation  and  further  appl !cations  for 
authorisation  are  currently  being  considered;  one  such 
application  relates  to  a  substance  considered  capable  of 
Increasing  milk  yields  by  upwards  of  5%.  No  authorisations 
for  milk  production  have  been  given  to  date. 
33.  CONCLUSIONS 
(a)  The  use  of  recombinant  BST  (rBST)  Is  capable  of  significant 
Increase  In  milk  yields.  It  Is  likely  to  be  the 
forerunner  of  other  products  capable  of  bringing  about  a 
substantial  Increase  In  meat  production. 
(b)  On  the  assumption  of  the  Community's  milk  Quota  regime 
continuing  beyond  1992,  the  use  of  BST  should  be  reflected 
In  a  reduction  In  the  number  of  dairy  cows  rather  than  an 
Increase  In  overall  milk  product lon;  this  Is  likely  to  be (c) 
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accompanied  by  a  release  of  resources  of  labour  and  capital 
Into  other  sectors  of  agriculture,  greater  concentration  of 
milk  product Jon  In  the  hands  of  the  larger  milk  producers 
and  greater  pressure  on  the  quota  regime. 
Apart 
which 
matter 
from 
has 
of 
the  Member  States  and  the  European  Par I lament 
adopted  a  resolution  on  the  Issue,  this  Is  a 
considerable  public  Interest  especially  among 
consumers,  producers,  Industry,  animal  welfare 
organisations  and  scientific  Interests.  While  directly 
opposing  positions  have  been  taken  up  by  consumers  and  the 
pharmaceutical  Industry,  most  other  Interested  parties  have 
taken  a  more  cautious  position,  advocating  further  studies 
and  Information. 
(d)  Apart  from  the  purely  scientific  aspects,  the  reservations 
expressed  by  the  Member  States  and  the  position  taken  up  In 
the  Par I lament  on  these  Issues,  as  well  as  the  considerable 
uncertainty  In  relation  to  consumer  reaction  and 
consequences  for  the  market,  requires  that  the  Community's 
approach  to  be  based  on  the  fullest  awareness  of  all  the 
Imp I I catIons. 
(e)  The  present  authorisation  process  for  use  of  BST  provides 
for  a  decision  at  national  level.  Other  chemical  products, 
administered  to  livestock  by  means  of  an  oral  preparat Jon 
for  nutritional  purposes  as  additives  In  feedlngstuffs, 
are  subject  to  a  Community  authorisation  procedure.  Whl le 
several  Member  States  have  expressed  reservations  about  use 
of  BST  there  may  not  be  unanimity  on  the  Issue.  This  could 
have  Implications  In  relation  to  free  movement  of  products. 
Examination  of  the  matter  by  the  Committee  on  Veterinary 
Medicinal  Products  (CVMP),  conducted  on  the  basis  of  the 
"safety",  "efficacy"  and  "quality"  of  the  product  Is  at  an 
advanced  stage.  It  Is  likely  that  Member  States  will  be 
faced  with  the  decision  of  whether  to  authorise  rBST  by  the 
end  of  this  year.  Studies  under  way  Into  other  aspects  eg 
milk  composition  and  quality,  consumer  reaction  etc  are  due 
to  be  completed  In  the  second  half  of  1990. - 17  -
(f)  It  Is  clear  that  a  situation  In  which  Member  States  may 
take  divergent  decisions  on  BST  must  be  avoided;  to  this 
end  the  Commission  wl I I  present  comprehensive  proposals  to 
Council  by  the  end  of  this  year.  Having  regard  to  the 
position  of  Parliament  and  the  general  public  concern  on 
these  Issues,  preparat lon  of  the  proposals  will  reQuire 
detailed  examination  of  the  most  appropriate  decision 
making  arrangements  and  structures  In  connection  with 
authorisation  of  all  productivity  enhancing  substances  In 
agriculture,  whether  veterinary  medicinal  products, 
Including  products  of  biotechnology,  or  feed  additives. 
(g)  It  Is  clear  also  that  sufficient  time  should  be  available 
to  assess  the  results  of  the  current  studies,  under  the 
aegis  of  the  CVMP  and  of  the  Commission.  At  the  same  time 
It  Is  essential  to  avoid  prolonged  uncertainty  that  would 
be  harmful  to  the  Interests  of  Industry,  especially 
biotechnology,  which  has  an  Important  role  In  the 
Community,  not  least  In  the  development  of  agriculture. 
(h)  It  will  be  Important  also  to  have  an  exchange  of  views  on 
the  Issues  raised  with  any  Interested  third  countries,  as 
It  Is  certain  that  the  Questions  raised  are  of  deep  concern 
and  Interest  not  Just  In  the  Community  but  also  In  the 
major  producer  and  consumer  countries. 
Recommendations 
It  Is  accordingly  proposed  that 
establish  an  evaluation  period 
administration  of  rBST.  This 
the  Counc I I 
up  to  the 
period  Is 
adopt  a  decision  to 
end  of  1990  on  the 
considered  to  be  the 
minimum  necessary  to  assess  the  results  of  ongoing  studies  and 
complete  the  new  arrangements  to  be  adopted  on  procedures.  The 
target  date  for  completion  of  some  of  the  studies  wl I I  have  to  be 
brought  forward  to  enable  the  Commission  to  fully  review  all 
aspects  In  twelve  months  time.  This  wl I I  provide  the  opportunity 
also  to  complete  the  necessary  contacts  with  Interested - 18  -
third  countries.  In  keeping  with  the  Community's  openness  on  the 
definitive  conclusion  on  this  Question,  It  Is  not  the  Intention 
to  prohibit  Imports  of  BST  or  of  products  derived  from  BST 
treated  animals  during  the  evaluation  period.  This  approach  Is 
not  considered  to  place  Community  ml  lk  producers  at  a  competitive 
disadvantage  In  practice. Annex  I 
Bodies  consulted  a)  THE  VETERINARY  ADVISORY  COMMITTEE 
represe~tatlve  of  Agricultural  Producers  (COPA),  Agricultural 
Cooperat lves  (COGECA).  Industry,  Confederat lon  of  the  Food  and 
Drink  Industries  of  the  EEC  (C.I.A.A.).  Commerce,  Comlte 
European  de  Liaison  des  Commerces  Agroal lmentalres 
(C.E.L.C.A.A.).  Workers,  European  Trade  Union  Confederation 
(E.T.U.C.).  Consumers,  Bureau  European  des  Unions  de 
Consommateurs  (B.E.U.C.),  European  Community  of  Consumer 
Cooperatives  (E.U.R.O.C.O.O.P.),  Confederation  des  Organisations 
Famlllales  de  Ia  CE  (C.O.F.A.C.E.).  Federation  of  Veterinarians 
of  the  European  Economic  Community  (FVE).  b)  The  ADVISORY 
COMMITTEE  ON  MILK  AND  MILK  PRODUCTS,  (representatives  of 
Producers/Cooperatives,  Dairy  and  Dairy  Related  Industries, 
Trade,  Workers  and  Consumers)  c)  OTHER  HEARINGS/ 
REPRESENTATIVES/OBSERVERS,  European  Community  Dairy  Industries 
(A.S.S. I .L.E.C.,  A.S.S. I .F.O.N.T.E.,  A.S.F.A.L.E.C.),  European 
Community  Dairy  Traders  (U.N.E.C.O.L.A.I.T.,  E.U.C.O.L.A.I.T), 
Eurogroup  for  Animal  Welfare,  European  Federation  of  Animal 
Health  (F.E.D.E.S.A.),  Compassion  In  World  Farming  (C.I.W.F.), 
European  Farmers  Coordination,  Deutscher  Tlerschutzbund, 
Tlerverschunger  Nordrheln-Westphal Ia  E.V.,  Gen-ethlsches 
Netzwork  G.E.N.,  Evangellsches  Bauernwerk  In  Wurttemberg,  Die 
Verbraucher  Initiative,  European  Campaign  Against  B.S.T.,  Working 
group  for  Lactlcal  Veterinary  Medicine  (A.G.K.T.),  EC  Livestock 
and  Meat  Trade  (U.E.C.B.V.),  EC  Meat  Processing  Industry 
(C.L.I.T.R.A.V.I.),  European  Retail  Trade  Associations  (C.L.D., 
C.E.C.D.),  EC  Meat  Wholesale  Trade  (A.E.C.G.V.),  The  London  Food 
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